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Abstract
Objective: This comparative in vitro study examined the
effects of all known gp130 cytokines on murine cortico-
troph AtT-20 cell function. Methods: Cytokines were
tested at equimolar concentrations from 0.078 to 10 nM.
Tyrosine phosphorylation of the signal transducer and
activator of transcription (STAT)3 and STAT1, the STAT-
dependent suppressor of cytokine signaling (SOCS)-3
promoter activity, SOCS-3 gene expression, STAT-de-
pendent POMC promoter activity and adrenocorticotrop-
ic hormone (ACTH) secretion were determined. Results:
Leukemia inhibitory factor (LIF), human oncostatin M
(OSM) and cardiotrophin (CT)-1 (LIFR/gp130 ligands), as
well as ciliary neurotrophic factor (CNTF) and novel neu-
rotrophin-1/B-cell stimulating factor-3 (CNTFR·/LIFR/
gp130 ligands) are potent stimuli of corticotroph cells in
vitro. In comparison, interleukin (IL)-6 (IL-6R/gp130 li-
gand) and IL-11 (IL-11R/gp130 ligand) exhibited only
modest direct effects on corticotrophs, while murine
OSM (OSMR/gp130 ligand) showed no effect. Conclu-
sion: (i) CNTFR complex ligands are potent stimuli of cor-
ticotroph function, comparable to LIFR complex ligands;
(ii) IL-6 and IL-11 are relatively weak direct stimuli of cor-
ticotroph function; (iii) differential effects of human and
murine OSM suggest that LIFR/gp130 (OSMR type I) but
not OSMR/gp130 (OSMR type II) are involved in cortico-
troph signaling. (iv) CT-1 has the hitherto unknown abili-
ty to stimulate corticotroph function, and (v) despite
redundant immuno-neuroendocrine effects of different
gp130 cytokines, corticotroph cells are preferably acti-
vated through the LIFR and CNTFR complexes.
Copyright © 2004 S. Karger AG, Basel
Introduction
The gp130 cytokine family currently encompasses sev-
en members, namely leukemia inhibitory factor LIF
(LIF), oncostatin M (OSM), cardiotrophin (CT)-1, ciliary
neurotrophic factor (CNTF), novel neurotrophin-1/B-cell
stimulating factor-3 (NNT-1/BSF-3), interleukin (IL)-6
and IL-11 [1–3]. The common receptor subunit gp130
associates with specific receptor subunits, resulting in the
gp130 Cytokines and Corticotroph
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heterodimeric receptor complexes LIFR/gp130 and
OSMR/gp130, the tripartite receptor complex CNTFR·/
LIFR/gp130 and the homodimeric receptor complexes
IL-6R/gp130 and IL-11R/gp130 [1–3]. Several gp130 cy-
tokines have been shown to be important modulators of
hypothalamo-pituitary-adrenal (HPA) and stimulates
corticotroph axis function in various states of stress or
inflammation [2–5]. Especially the action of LIF has been
well characterized at pituitary corticotroph level, using
the in vitro model of murine corticotroph AtT-20 cells.
LIF binds to the LIFR/gp130 complex and stimulates cor-
ticotroph Janus kinase (Jak) and signal transducer and
activator of transcription (STAT) signaling and subse-
quent STAT-dependent POMC gene expression and adre-
nocorticotropic hormone (ACTH) secretion [2, 5]. Also,
the role of STAT-dependent suppressor of cytokine sig-
naling (SOCS)-3 gene expression and its role as an endoge-
nous negative regulator of cytokine-induced corticotroph
function has been examined by experiments using LIF as
a corticotroph stimulus [6]. Stimulatory effects on cortico-
troph cell function in vitro have also been described for
human OSM (hOSM) [7–11], CNTF and NNT-1/BSF-3
[12], IL-6 [13–16] and IL-11 [17], respectively. However,
as these effects have been investigated under various con-
ditions, these studies cannot show the relative potency of
each gp130 cytokine in corticotroph function. To the best
of our knowledge, no studies have been published regard-
ing the effects of CT-1 and murine OSM (mOSM) on cor-
ticotroph cells.
In the current study, we compared the effects of equi-
molar concentrations of all known gp130 cytokines on
murine corticotroph AtT-20 cell function in vitro. De-
spite obvious redundancy of gp130 cytokines as immuno-
neuroendocrine modulators of HPA axis activity, this
study demonstrates a specific role of gp130 cytokines in
the corticotroph-stimulating function. Our data show that
the ligands of the LIFR and CNTFR complexes are the
major direct stimuli of corticotroph function, as indicated
by STAT tyrosine phosphorylation, STAT-dependent
SOCS-3 promoter activity and gene expression and
POMC promoter activity and ACTH secretion.
Materials and Methods
Materials
Recombinant human (rh)NNT-1/BSF-3 was expressed in Esche-
richia coli [18] and stocked in a solution containing 5 mM sodium
citrate, pH 4. All other cytokines tested were diluted in the same sodi-
um citrate buffer, and the buffer solution was used as a control.
Recombinant murine (rm)LIF was purchased from Chemicon Inter-
national (Temecula, Calif., USA). All other cytokines, i.e. rhOSM,
rmCT-1, rhCNTF, rmIL-6, rmIL-11 and rmOSM were purchased
from R&D Systems (Minneapolis, Minn., USA).
Cell Culture
AtT-20/D16v-F2 cells were cultured in DMEM supplemented
with 10% fetal calf serum as described recently [12]. Cells were
appropriately plated and grown for 48 h. Afterwards, cells were
preincubated with serum-depleted medium (containing 0.2% BSA)
for 24 h and subsequently incubated with equimolar concentrations
of each cytokine tested.
Northern Blot Analysis
Northern blot analysis was performed as described recently [12].
Briefly, RNA was extracted using TRIZOL® (Invitrogen, Karlsruhe,
Germany) and 20 Ìg total RNA per lane were electrophoresed and
transferred to a nylon membrane. Using random-primed DNA label-
ing, a SOCS-3 probe template (nt 15–762, GeneBank Accession
U88328) and a ß-actin DECAprobe® (Ambion, Austin, Tex., USA)
were labeled with (·-32P)CTP. Following hybridization with Quick-
Hyb Rapid® (Stratagene, La Jolla, Calif., USA) autoradiographs were
exposed to Kodak Biomax MS® film (Eastman Kodak, Rochester,
N.Y., USA).
Luciferase Assay
Transient transfection of AtT-20 cells with a –706/+64 rat
POMC promoter-luciferase construct in PGEM7Z vector (kindly
provided by Dr. Malcolm Low, Vollum Institute, Portland, Oreg.,
USA) or a –2757/+929 mSOCS-3 promoter-luciferase construct in
pGL3Basic vector [19] was performed with Superfect® (Quiagen,
Hilden, Germany), as described recently [12]. In the current experi-
ments, luciferase activities were measured in untreated controls and
cells treated with equimolar concentrations (10 nM ) of various
gp130 cytokines. The relative increase in untreated vs. stimulated
luciferase activity was determined for each experiment.
Protein Extraction and Western Blotting 
Protein extraction, SDS gel electrophoresis and Western blotting
was performed as described recently [12]. Tyrosine phosphorylation
was detected with specific primary antibodies against phosphorylat-
ed STAT3 (pSTAT3) and pSTAT1 (Upstate Biotechnology, Lake
Placid, N.Y., USA) and a peroxidase conjugated secondary antibody
(Pierce, Rockford, Ill., USA). Peroxidase was detected by the chemi-
luminescent substrate SuperSignal West Dura Extended Duration
Substrate (Pierce) and membranes exposed to XOMAT-AR® film
(Eastman Kodak). For the determination of protein loading, blots
were stripped and re-incubated with antibodies to STAT3 and
STAT1 (Santa Cruz Biotechnology, Santa Cruz, Calif., USA), respec-
tively.
ACTH Assay
ACTH was measured with a commercial radioimmunoassay
(Diagnostic System Laboratories, Webster, Tex., USA) in the super-
natants of AtT-20 cells stimulated with various gp130 cytokines for
24 h.
Statistical Analysis
Densitometric analysis of specific bands in Northern blots was
performed with NIH Image 1.59 software, and JMP 5.0.1 software
was used for statistical analysis. The data are expressed as means B
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Fig. 1. Effects of gp130 cytokines on cortico-
troph STAT3 phosphorylation. Corticotroph
AtT-20 cells were incubated with equimolar
concentrations (10 nM ) of various gp130
cytokines for 5 and 15 min, respective-
ly. Tyrosine phosphorylation of STAT3
(pSTAT3) and protein loading of the respec-
tive STAT3 protein were determined by the
use of specific antibodies. A Using densi-
tometric analysis, the ratio of pSTAT3 vs.
STAT3 for each treatment group was deter-
mined and the respective ratio of the control
group was set at 1.0. The relative ratio of
tyrosine STAT3 phosphorylation was calcu-
lated in comparison to this negative control
group. Means B SE of 3 independently per-
formed experiments are shown (significant
differences are indicated: * p ! 0.05; ** p !
0.01; *** p ! 0.001, vs. control, ). B One rep-
resentative Western blot out of 3 per-
formed.
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SE of at least three independent experiments. The mean of a single
treatment group versus the mean of a single control group were com-
pared using Student’s t test and p ! 0.05 was considered statistically
significant.
Results
Tyrosine Phosphorylation of STAT3 and STAT1 by
Various gp130 Cytokines
Tyrosine phosphorylation of STAT3 at 5 min was
induced 17- to 20-fold by LIF, hOSM and CT-1, 13-fold
by NNT-1/BSF-3 but 6-fold by CNTF, and approximately
3-fold by IL-6 and IL-11, respectively (fig. 1). At 15 min,
tyrosine phosphorylation of STAT3 was induced 20- to
21-fold by LIF, hOSM and CT-1, 14- to 19-fold by CNTF
and NNT-1/BSF-3 and 7- to 12-fold by IL-11 and IL-6,
respectively (fig. 1).
Tyrosine phosphorylation of STAT1 at 5 min was
induced 5- to 11-fold by hOSM, CT-1 and LIF, 17-fold by
NNT-1/BSF-3 but only 2-fold by CNTF, and was hardly
induced by IL-6 and IL-11 (fig. 2). At 15 min, tyrosine
phosphorylation of STAT1 was induced 14- to 22-fold by
hOSM, LIF and CT-1, 14-fold by NNT-1/BSF-CNTF-3
but only 5-fold by CNTF and 2- to 5-fold by IL-11 and
IL-6, respectively (fig. 2).
No effect on STAT3 or STAT1 phosphorylation was
found for mOSM (fig. 1, 2), although high bioactivity and
STAT activation of this cytokine preparation could be
demonstrated in adrenocortical Y-1 cells (data not
shown).
In a dose-response study, tyrosine phosphorylation of
STAT3 by various gp130 cytokines ranging from 0.078 to
10 nM was examined (2 independently performed experi-
ments, fig. 3A, B). STAT3 phosphorylation was detected
with concentrations as low as 0.078 to 0.312 nM for
hOSM, LIF, CT-1, and NNT-1/BSF-3. In contrast, higher
concentrations of 0.625–2.5 nM were required to induce
STAT3 phosphorylation by CNTF, IL-11 and IL-6. Cyto-
kine-induced STAT3 phosphorylation seemed to reach a
plateau when using concentrations of 5.0–10.0 nM of
each respective cytokine. mOSM did not induce STAT3
phosphorylation in AtT-20 cells at any concentration
tested.
SOCS-3 Promoter Activity and Gene Expression by
Various gp130 Cytokines
Promoter activity of a murine –2757/+929 SOCS-3
promoter-luciferase construct (fig. 4A) and SOCS-3
mRNA expression (fig. 4B) were examined following in-
cubation of AtT-20 cells with different gp130 cytokines in
an equimolar concentration of 10 nM. SOCS-3 promoter
activity was significantly stimulated 3- to 5-fold above
gp130 Cytokines and Corticotroph
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Fig. 2. Effects of gp130 cytokines on cortico-
troph STAT1 phosphorylation. Corticotroph
AtT-20 cells were incubated with equimolar
concentrations (10 nM ) of various gp130
cytokines for 5 and 15 min, respective-
ly. Tyrosine phosphorylation of STAT1
(pSTAT1) and protein loading of the respec-
tive STAT1 protein was determined by the
use of specific antibodies. A Using densi-
tometric analysis, the ratio of pSTAT1 vs.
STAT1 for each treatment group was deter-
mined and the respective ratio of the control
group was set at 1.0. The relative ratio of
tyrosine STAT1 phosphorylation was calcu-
lated in comparison to this negative control
group. Means B SE of 3 independently per-
formed experiments (significant differences
are indicated: * p ! 0.05; ** p ! 0.01; *** p !
0.001, vs. control). B One representative
Western blot out of 3 performed.
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Fig. 3. Dose-response curve of gp130 cytokines on corticotroph STAT3 phosphorylation. A In a dose-response study,
corticotroph AtT-20 cells were incubated with different gp130 cytokines in concentrations ranging from 0.078 to
10.0 nM. Tyrosine pSTAT3 was demonstrated by a specific antibody. Equal protein loading was verified with an
antibody against total STAT3 (data not shown). One representative Western blot out of 2 performed is shown.
B Normalized densitometry data of A.
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Fig. 4. Effects of gp130 cytokines on cortico-
troph SOCS-3 promoter activity and gene
expression. A Corticotroph AtT-20 cells
were incubated with equimolar concentra-
tions (10 nM ) of various gp130 cytokines for
6 h. Reporter gene activity of a transiently
transfected –2757/+929 murine SOCS-3
promoter-luciferase (luc) construct was as-
sayed. Reporter gene activity induced by the
various gp130 cytokines was calculated as x-
fold increase in comparison to an unstimu-
lated control. Significant differences are in-
dicated: ** p ! 0.01; *** p ! 0.001, vs. con-
trol. B AtT-20 cells were incubated with
equimolar concentrations (10 nM ) of var-
ious gp130 cytokines for 45 min. SOCS-3
mRNA expression was determined by
Northern blot analysis. Shown is one repre-
sentative Northern blot out of 3 performed.
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baseline by NNT-1/BSF-3, CNTF, CT-1, LIF and hOSM.
In contrast, no significant increase in promoter activity
could be detected in this series of experiments by mOSM,
IL-6 and IL-11, respectively. Results are the mean values
of four independently performed experiments with n = 3
per experiment (fig. 4A). Using Northern blot analysis,
SOCS-3 mRNA expression was potently induced at 45
min by NNT-1/BSF-3, CNTF, CT-1, LIF and hOSM. A
weak stimulation was also induced by IL-6 and IL-11,
while mOSM exhibited no effect. A representative experi-
ment out of three is shown (fig. 4B).
POMC Promoter Activity and ACTH Secretion by
Various gp130 Cytokines
Promoter activity of a –706/+64 rat POMC promot-
er-luciferase construct (fig. 5A) and ACTH secretion
(fig. 5B) was examined following incubation of AtT-20
cells with different gp130 cytokines in an equimolar con-
centration of 10.0 nM. POMC promoter activity was
significantly stimulated 2- to 4-fold above baseline by
NNT-1/BSF-3, CNTF, CT-1, LIF and hOSM. In contrast,
no significant increase in promoter activity was detected
in this series of experiments by mOSM, IL-6 and IL-11,
respectively. Results are the mean values of four indepen-
dently performed experiments with n = 3 per experiment.
Following incubation of AtT-20 cells for 24 h with equi-
molar concentrations (10.0 nM) of each cytokine tested,
ACTH secretion was stimulated approximately 2.0-fold
by NNT-1/BSF-3 and CNTF, approximately 2.5- to 3.0-
fold by CT-1, LIF and hOSM, and approximately 1.5-fold
by IL-6 and IL-11, respectively. mOSM did not cause a
significant stimulation of ACTH secretion above baseline
(fig. 5B).
Discussion
Our study demonstrates that LIF, hOSM and CT-1
(LIFR/gp130 ligands), as well as CNTF and NNT-1/
BSF-3 (CNTFR·/LIFR/gp130 ligands) are potent stimuli
of murine corticotroph AtT-20 cell function. IL-11 (IL-
11R/gp130 ligand) and IL-6 (IL-6R/gp130 ligand) are rel-
atively weak direct stimuli of corticotroph function,
whereas mOSM (OSMR/gp130 ligand) exhibits no bioac-
tivity on corticotroph AtT-20 function.
CNTFR Complex Ligands Are Potent Stimuli of
Corticotroph Function, Comparable to LIFR Complex
Ligands
The CNTFR·/LIFR/gp130 complex binds specifically
CNTF as well as the recently cloned cytokine NNT-1/
BSF-3 [18, 19–22]. Recently, we have demonstrated
NNT-1/BSF-3 to be a potent stimulator of corticotroph
function in vitro inducing Jak-STAT-dependent gene ex-
pression, negatively regulated by SOCS-3 [12]. CNTF was
also found to be a stimulator of corticotroph function
[12]. The current data, using equimolar concentrations of
each cytokine tested, confirm our previous finding that
gp130 Cytokines and Corticotroph
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Fig. 5. Effects of gp130 cytokines on corticotroph POMC promoter
activity and ACTH secretion. Significant differences are indicated:
* p ! 0.05; ** p ! 0.01; *** p ! 0.001 vs. control. A Corticotroph
AtT-20 cells were incubated with equimolar concentrations (10 nM )
of various gp130 cytokines for 6 h. Reporter gene activity of a tran-
siently transfected –706/+64 rat POMC promoter-luciferase (luc)
construct was assayed. Reporter gene activity induced by the various
gp130 cytokines was calculated as x-fold increase in comparison to
an unstimulated control. B AtT-20 cells were incubated with equimo-
lar concentrations (10 nM ) of various gp130 cytokines for 24 h and
ACTH was assayed in the supernatants. ACTH secretion induced by
the various gp130 cytokines was calculated as x-fold increase in com-
parison to an unstimulated control.
NNT-/BSF-3 and CNTF are potent modulators of corti-
cotroph function. NNT-1/BSF-3 is a similarly potent
modulator of corticotroph function as are LIF, hOSM and
CT-1 (LIFR/gp130 ligands). In comparison to NNT-1/
BSF-3, CNTF seems to be less potent in the stimulation of
corticotroph function in vitro.
IL-6 and IL-11 Are Relatively Weak Direct Stimuli of
Corticotroph Function
IL-6R is expressed in fetal [10] and postmortem hu-
man pituitaries [23] and pituitary corticotroph adenomas
[23]. IL-6 has been demonstrated to stimulate POMC
gene expression and ACTH secretion in human cortico-
troph adenoma cell cultures [24]. Also, the IL-6R is
expressed in murine corticotrophs [25] and corticotroph
AtT-20 cells (data not shown). In AtT-20 cells, IL-6 has
been reported to stimulate POMC gene expression [15]
and ACTH secretion [13, 14, 16]. Also, in our current
study, IL-6 modestly but significantly stimulates ACTH
secretion, but demonstrates no significant effect on the
POMC promoter construct. IL-6 also fails to significantly
stimulate STAT-dependent SOCS-3 promoter activity
and has only a slight effect on SOCS-3 gene expression. In
comparison to equimolar concentrations of other gp130
cytokines, IL-6 shows only a minor effect as direct stimu-
lator of corticotroph AtT-20 cell function in vitro. These
data are similar to our previous observation of IL-6 exhib-
iting no significant stimulation of STAT-dependent
SOCS-3 promoter activation in AtT-20 cells [26]. How-
ever, these in vitro findings do not diminish the putative
major role of IL-6 as an inflammatory cytokine stimulat-
ing HPA axis activation. Firstly, IL-6 has been shown to
induce the secretion of arginine vasopressin from the
hypothalamus [27] and corticotrophin-releasing hormone
from immortalized cell lines [28], thus IL-6 probably indi-
rectly stimulates corticotroph function via hypothalamic
activation. However, IL-6 injection in mice deficient in
corticotrophin-releasing hormone also results in a pro-
found increase in ACTH levels, even higher than in wild-
type animals [25]. This might be explained by indirect
effects of IL-6 via other paracrine/endocrine mediators as
well as some direct stimulatory effects of IL-6 on pituitary
corticotrophs. Paracrine effects of IL-6 might also be
responsible for the finding of IL-6 being almost equally
potent to LIF and hOSM in inducing ACTH secretion
from primary human fetal pituitary cultures [10]. Sec-
ondly, IL-6 is a potent direct stimulator of adrenocortical
function in vitro [29, 30].
Expression of the IL-11R has been demonstrated in
postmortem human pituitaries [17, 23] and pituitary cor-
ticotroph adenomas [23], as well as murine pituitaries
[17] and corticotroph AtT-20 cells [17]. We have pre-
viously shown IL-11 to stimulate STAT-dependent
SOCS-3 and POMC gene expression and ACTH secretion
in AtT-20 cells [17]. The current data, using equimolar
amounts of each cytokine tested, exhibit IL-11 to be a rel-
atively weak inducer of corticotroph function in compari-
son to other gp130 cytokines. While in our previous stud-
ies a modest but significant effect of IL-11 on SOCS-3 and
POMC promoter activity could be demonstrated [17, 31],
in the current study no significant induction of SOCS-3
and POMC promoter activity was observed. These dis-
crepant findings might be explained by varying condi-
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tions for cell culture and luciferase assay. This observa-
tion again underlines the necessity for comparative stud-
ies in order to directly compare the potency of different
cytokines.
hOSM and mOSM Have Different Effects on Murine
Corticotrophs, Suggesting that LIFR/gp130 (OSMR
Type I), but Not OSMR/gp130 (OSMR Type II) Is
Important in Corticotroph Signaling
We show differential effects of human and murine
OSM on corticotroph function. While cloning of hOSM
has been reported in 1989 [32], the cloning of mOSM was
first published in 1996 [33]. Earlier studies using hOSM
demonstrated stimulation of basal and corticotrophin-
releasing hormone-induced POMC transcription and
ACTH secretion in murine corticotroph AtT-20 cells [7–
9] as well as ACTH secretion in rat primary pituitary cul-
tures [11, and Kim person. commun.] and in human fetal
primary pituitary cultures [10]. In human cells, hOSM
can bind to the LIFR/gp130 (OSMR type I) as well as to
the OSMR/gp130 (OSMR type II) complex [34–36]. Due
to strict species specificity of OSM binding to the OSMR/
gp130 complex [36], in murine cells hOSM binds exclu-
sively to the LIFR/gp130 complex [34]. Thus, the earlier
studies [7–9, 11] did not examine the putative role of the
OSMR/gp130 complex in corticotroph function, but rath-
er the LIFR/gp130 physiology [34]. We therefore com-
pared in murine corticotroph AtT-20 cells the effects of
hOSM, acting as a ligand to the LIFR/gp130 complex in
murine cell systems [34, 36], with the effects of mOSM,
binding exclusively to the OSMR/gp130 complex but fail-
ing to bind to the LIFR/gp130 complex [34–36]. Incuba-
tion of AtT-20 cells with hOSM resulted in a potent stim-
ulation of STAT3 and STAT1 comparable to the stimula-
tion induced by LIF. In addition, STAT-dependent
POMC promoter activity and ACTH secretion was also
potently stimulated by hOSM, as had been described
before [7–9]. In contrast, incubation of AtT-20 cells with
mOSM failed to induce any STAT-dependent down-
stream events (fig. 1–5), while bioactivity of the mOSM
used was demonstrated in murine adrenocortical Y-1 cells
[37]. RT-PCR expression studies of the different receptor
subunits involved in LIFR/gp130 and OSMR/gp130 com-
plex formation exhibited murine pituitary tissue and cor-
ticotroph AtT-20 cells to express gp130 and LIFR sub-
units [12]. In contrast, expression of the OSMR subunit
was only detected in pituitary tissue, while AtT-20 cells
did not express the OSMR subunit (data not shown). Our
data demonstrate hOSM and mOSM to display differ-
ential effects on murine corticotroph function. While
hOSM (associated with OSMR type I) is a potent stimulus
of corticotroph function, mOSM (association with OSMR
type II) has no significant effects.
CT-1 Is a New Modulator of Corticotroph Function
CT-1 has originally been named for its ability to stimu-
late hypertrophy of cardiac myocytes [38]. CT-1 is ex-
pressed in the heart and various other tissues [38]. CT-1
signaling involves the LIFR/gp130 complex [39]. In addi-
tion, for CT-1 signaling a third specific receptor compo-
nent has been suggested [39], which would result in a CT-
1R/LIFR/gp130 complex similar to the tripartite
CNTFR·/LIFR/gp130 complex. In vivo, systemic ad-
ministration of CT-1 alone and combined with IL-1
resulted in an increase in corticosterone levels [40], which
might be due to HPA axis activation at various levels, e.g.
pituitary or adrenal. In AtT-20 cells, CT-1 potently stimu-
lates corticotroph STAT phosphorylation, STAT-depen-
dent SOCS-3 promoter activity and gene expression as
well as ACTH secretion. The magnitude of corticotroph
activation by CT-1 is comparable to the effects observed
by LIF, hOSM, NNT-1/BSF-3 or CNTF. Thus, we could
demonstrate CT-1 to be a potent modulator of cortico-
troph cell function in vitro. No expression of CT-1 could
be demonstrated by RT-PCR in postmortem human
pituitaries and various pituitary tumors including cortico-
troph adenomas [23], suggesting no role of CT-1 as an
auto-/paracrine factor in pituitary function. However,
CT-1 can be measured in the circulation, and CT-1 levels
in blood were found to correlate with the degree of heart
failure in man [41, 42]. So, stimulatory effects of CT-1 on
pituitary corticotroph function might be of endocrine
instead of auto-/paracrine mode. Patients with chronic
heart failure and cachexia have been shown to exhibit
increased serum levels of cortisol [43], which – according
to our data – might be partially mediated by endocrine
stimulation of the HPA axis by CT-1. This hypothesis
merits further evaluation.
In summary, this comparative in vitro study of the
action of gp130 cytokines on murine corticotroph AtT-20
cells shows LIF, hOSM, CT-1, CNTF and NNT-1/BSF-3
to be major stimuli of the corticotroph Jak-STAT signal-
ing cascade. In contrast, IL-6 and IL-11 show only modest
effects on corticotroph function, whereas no significant
effect of mOSM on corticotroph function could be de-
tected. In conclusion, LIFR ligands (LIF, hOSM, CT-1)
and CNTFR ligands (CNTF, NNT-1/BSF-3) are similarly
potent direct stimuli of corticotroph function in vitro.
CT-1 is a hitherto unknown modulator of corticotroph
function in vitro, which might act by endocrine rather
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than para-/autocrine mechanisms. Differential effects of
hOSM and mOSM on corticotroph function demonstrate
the LIFR/gp130 complex (OSMR type I) but not OSMR/
gp130 (OSMR type II) to be of physiologic relevance in
neuroimmunoendocrine modulation of corticotroph
function. Thus, despite redundant effects of several gp130
cytokines on corticotroph function, this study could dem-
onstrate specific differences in the potency of different
gp130 cytokines to activate corticotroph Jak-STAT sig-
naling and function. This specific pattern of gp130 cyto-
kine action on corticotrophs further contributes to our
understanding of the neuroimmunomodulation of corti-
cotroph function. Further comparative studies should
also examine differences in gp130 cytokines with respect
to their ability to directly induce corticotroph versus adre-
nocortical function. The – at first glance –redundant neu-
roimmunoendocrine cytokine network might turn out to
have distinct specific ‘major players’ at corticotroph as
well as at adrenocortical level.
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